Waverly Advisors LLC Has $9.14 Million Holdings in Medtronic PLC $MDT

Waverly Advisors LLC boosted its stake in Medtronic PLC (NYSE:MDT) by 9.9% in the second quarter, HoldingsChannel.com reports. The firm owned 116,780 shares of the medical technology company’s stock after buying an additional 10,541 shares during the period. Waverly Advisors LLC’s holdings in Medtronic were worth $9,136,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MDT. Monetary Solutions Ltd bought a new stake in shares of Medtronic in the 4th quarter valued at about $27,000. Acumen Wealth Advisors LLC bought a new position in shares of Medtronic during the fourth quarter worth about $29,000. IAG Wealth Partners LLC bought a new position in shares of Medtronic during the second quarter worth about $30,000. Imprint Wealth LLC acquired a new position in shares of Medtronic in the third quarter worth approximately $31,000. Finally, Basepoint Wealth LLC acquired a new position in shares of Medtronic in the fourth quarter worth approximately $32,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Trading Down 0.4%

NYSE MDT opened at $92.01 on Thursday. The stock has a market capitalization of $117.69 billion, a P/E ratio of 22.66, a P/E/G ratio of 2.17 and a beta of 0.56. The business has a 50 day simple moving average of $87.58 and a 200 day simple moving average of $85.17. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The company’s revenue was up 13.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Research analysts expect that Medtronic PLC will post 5.96 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Friday, September 25th. Medtronic’s payout ratio is presently 70.94%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on MDT shares. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research report on Monday, August 10th. TD Cowen boosted their price target on shares of Medtronic from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, August 28th. Evercore set a $105.00 price objective on shares of Medtronic in a research note on Monday, July 6th. BTIG Research increased their price objective on shares of Medtronic from $91.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, September 1st. Finally, JPMorgan Chase & Co. lowered their target price on shares of Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Nineteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average target price of $103.92.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic raised its fiscal 2027 organic revenue-growth outlook and increased the lower end of its adjusted earnings forecast after quarterly results exceeded expectations. Cardiovascular devices were the primary growth engine, while surgical products also contributed to broad-based expansion. Medtronic Raised its Outlook as Heart Devices Accelerate, But Can the Momentum Last?
• Positive Sentiment: Recent results showed 13.7% year-over-year revenue growth, $9.76 billion in quarterly revenue versus a $9.55 billion consensus estimate, and adjusted EPS of $1.45 versus expectations of $1.39. The performance suggests improving demand across Medtronic’s cardiovascular and surgical franchises. Medtronic Q1 2027 Earnings Call Transcript
• Positive Sentiment: Medtronic remains attractive to income-focused investors, offering a roughly 3% dividend yield and having increased its dividend for 49 consecutive years. The company is potentially two years away from reaching “Dividend King” status, which could support long-term shareholder interest. Medtronic Is on the Cusp of Becoming a Dividend King
• Neutral Sentiment: Analysts view the improved growth and earnings outlook favorably, but investors remain selective because Medtronic must demonstrate that its cardiovascular acceleration is sustainable beyond the latest quarter.
• Negative Sentiment: Margin pressure, foreign-exchange effects, execution risks and intense medical-device competition could limit the benefit of stronger sales growth. These concerns help explain why the stock has not fully reflected the improved outlook. Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum

Medtronic Profile

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.